While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...
Terns Pharmaceuticals reports its targeted leukemia drug maintained and even boosted molecular response rates in ...
The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309 ...
News-Medical.Net on MSN
Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...
14hon MSN
Continuous and fixed-duration treatments result in similar outcomes for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...
The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...
Terns Pharmaceuticals reported positive data for its drug designed to treat leukemia, sending shares up. The oncology company said Monday that its treatment TERN-701 showed a 64% major molecular ...
Stocktwits on MSN
Terns Pharmaceuticals stock jumps after new leukemia drug data show strong patient responses
Terns Pharmaceuticals (TERN) shares rose 12% on Monday after the company reported additional positive Phase 1 results for its ...
Azacitidine and decitabine belong to a class of antineoplastic agents known as DNA methyltransferase inhibitors (DMTIs). Each is paired with cedazuridine, a cytidine deaminase inhibitor, to help the ...
In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results